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Loss of liver mass and ischemia/reperfusion injury (IRI) are major contributors to postresectional liver failure and small-for-size
syndrome. Mesenchymal stromal cell- (MSC-) secreted factors are described to stimulate regeneration after partial hepatectomy.
This study investigates if liver-derived MSC-secreted factors also promote liver regeneration after resection in the presence of IRI.
C57BL/6 mice underwent IRI of 70% of their liver mass, alone or combined with 50% partial hepatectomy (PH). Mice were treated
withMSC-conditionedmedium (MSC-CM) or unconditionedmedium (UM) and sacrificed after 6 or 24 hours (IRI group) or after
48 hours (IRI + PH group). Blood and liver tissue were analyzed for tissue injury, hepatocyte proliferation, and gene expression.
In the IRI alone model, serum ALT and AST levels, hepatic tissue damage, and inflammatory cytokine gene expression showed no
significant differences between both treatment groups. In the IRI + PHmodel, significant reduction in hepatic tissue damage as well
as a significant increase in hepatocyte proliferation was observed afterMSC-CM treatment. Conclusion. Mesenchymal stromal cell-
derived factors promote tissue regeneration of small-for-size livers exposed to ischemic conditions but do not protect against early
ischemia and reperfusion injury itself. MSC-derived factors therefore represent a promising treatment strategy for small-for-size
syndrome and postresectional liver failure.
1. Introduction
Advances in surgical techniques have enabled large liver
resections as well as split and living donor liver transplanta-
tion (LDLT). Transplantation of partial (living donor) liver
grafts was introduced to help overcome donor organ scarcity
and reduce waitlist mortality. Living donors undergo resec-
tion of approximately 40–60% of their liver volume, which
is transplanted into the recipient. Without the exceptional
capacity of the liver to regenerate and thereby compensate for
tissue loss and restore homeostasis, these extensive resections
and partial graft transplantations would not be possible [1–
3]. Nevertheless, in case of adult to adult living donor liver
transplantation both donors and partial graft recipients end
up with a small-for-size liver, which is still associated with
significant morbidity and even mortality [2, 4, 5]. In an
attempt to decrease donor risk, smaller grafts (such as the
left lobe of the liver) can be used, but this is limited by
the increased risk of the recipient to develop small-for-size
syndrome [6].
In these settings, both loss of a substantial part of
the liver mass and the inevitable ischemia and reperfusion
injury (IRI) are major mechanisms of hepatic injury [7, 8].
Effective therapeutic strategies to protect against IRI, enhance
regeneration, and stimulate recovery could minimize donor
and recipient risk.
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A promising new therapeutic intervention can be found
inmesenchymal stromal/stem cell (MSC) based strategies [9–
12]. At the early beginning of research on MSCs they were
thought only to provide a supportive niche for hematopoietic
stem cells in the bone marrow. Meantime, they have been
reported to reside inmultiple tissue compartments, including
lung, liver, and adipose tissue [13–15]. Our group showed
that the adult human liver harbors a population of MSCs,
highly similar to bone marrow MSCs in their multilineage
differentiation potential as well as their genome-wide gene
expression profiles, which is mobilized from liver grafts at
time of transplantation [14, 16].These liver-derivedMSCs (L-
MSCs) can be retrieved from the organ preservation solution
and appear to have immunosuppressive capacities as well as
multilineage differentiation potential [17]. Furthermore, we
have reported that the trophic factors secreted by these L-
MSCs stimulate liver regeneration after surgical resection,
mainly by promoting hepatocyte proliferation and altering
expression levels of regeneration-related genes [18, 19].
Previous research revealed that MSC-secreted trophic
factors include a broad spectrum of growth factors, che-
mokines, and cytokines related to cellular growth and prolif-
eration as well as immunomodulation in the setting of toxic
liver injury and hepatic failure [20, 21]. In those experiments,
a significant survival benefit with decreased signs of liver
injury and increased hepatocyte proliferationwas gainedwith
conditioned medium, enriched mainly for IGFBP-1, leptin,
and CCL2, but also containing IL-6 and TNF-𝛼.
The use of these MSC-secreted factors in a clinical setting
may have important advantages over the use of MSCs: there
is no risk of rejection or possible malignant transformation
and the factors can be produced ready-to-use in large clinical
grade quantities [22]. The aim of this study is to investigate
whether L-MSC-secreted factors are as effective to ameliorate
hepatic IRI as well as to promote regeneration in a clinically
relevant model of combined IRI and partial liver resection.
2. Materials and Methods
2.1. Animals. Male C57BL/6 mice (age 7–10 weeks) were
obtained from Jackson Laboratories (Bar Harbor, ME, USA)
and maintained in the animal facility on a 12/12 hour
light/dark schedule. The animals had free access to food and
drinking water. All animal experiments were performed with
approval of the institutional animal welfare committee.
2.2. Human L-MSC Cultures and Conditioned Medium.
Liver-derived MSCs were obtained from the UW organ
preservation solution (Viaspan, Bristol-Myers Squibb, Woer-
den, Netherlands), collected after cold storage of human liver
grafts for transplantations performed at the Erasmus Med-
ical Center, Rotterdam, Netherlands. The Medical Ethical
Council of the Erasmus Medical Center and the Institutional
Biological Safety Committee of the Children’s Hospital of
Philadelphia approved the use of human donor material for
medical research.
Mononuclear cells were isolated from the collected
preservation fluids by density gradient centrifugation using
Ficoll-Paque Plus (GE Healthcare, Uppsala, Sweden) and
put into culture as previously described [14, 19]. Culture
medium consisted of MEM alpha (Invitrogen, Grand Island,
NY,USA) supplementedwith 15% fetal bovine serum (Sigma-
Aldrich, St. Louis, MO, USA), L-glutamine (Invitrogen), and
penicillin and streptomycin (Invitrogen). The last three days
before collecting the supernatant, L-MSCs were cultured
under serum-free conditions. Culture medium was therefore
changed to MEM alpha supplemented with 0.05% bovine
serumalbumin (Sigma-Aldrich), L-glutamine, penicillin, and
streptomycin.TheMSC-conditioned culture medium (MSC-
CM) was collected three days after medium change of L-
MSC cultures frompassage 6–10.MSC-CMwas concentrated
approximately 25-fold by filtration with 3-kD molecular cut-
off filters (Amicon Ultra, Millipore, Carrigtwohill, Ireland).
2.3. Surgical Procedures and MSC-CM Treatment. C57BL/6
mice were anesthetized and injected intraperitoneally with
100U/kg heparin. After a midline laparotomy, ischemia and
reperfusion injury (IRI) with or without partial hepatectomy
(PH) was induced. All procedures were performed under
clean conditions.
In the IRI alone group, 90 minutes of ischemic injury of
70% of the liver was induced by clamping the blood supply to
the left lateral and median lobes with microvascular clamps.
In this way the right lateral and caudate lobes served as a
portacaval shunt, allowing survival of the animals during the
ischemic period.
In the combined (IRI + PH) group, 60 minutes of
ischemic injury was induced as described above, after which
the right part of the median lobe, the right lateral lobe,
and the caudate lobes were ligated and resected, leaving
approximately 50% ischemic liver tissue. The combination
of ischemic injury with 50% hepatectomy did not allow an
ischemic period of more than 60 minutes, without affecting
survival. During the ischemic period in both groups, the
abdominal cavity was covered with saline-moistened gauzes
and the animals were kept under anesthesia on a warming
plate to conserve body temperature. At the end of the surgical
procedures the peritoneum and skin were sutured separately.
In both groups, half of the animals were treated with
200𝜇L of the concentrated serum-free MSC-CM, injected
intraperitoneally at the end of the surgical procedure. The
other animals were treated similarly with concentrated
serum-free unconditioned medium (UM). This uncondi-
tioned medium consisted of culture medium treated exactly
the same as the serum-free MSC-CM but without the pres-
ence of L-MSCs. The animals in the IRI alone group were
sacrificed either 6 or 24 hours after surgery, based on existing
literature on liver IRI, which shows clearest signs of tissue
damage and highest levels of serum injury markers at these
time points. The animals in the IRI + PH group were treated
a second time with MSC-CM or UM after 24 hours and were
sacrificed 48 hours after surgery, as this was the time point
showing largest effects on hepatocyte proliferation in our
previous study [18]. From all animals (𝑛 = 8 per study group)
blood and liver tissue were collected to further investigate the
effects ofMSC-CMon serummarkers of liver function, tissue
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injury, hepatocyte proliferation, and hepatic gene expression
in the early phase after liver injury.
2.4. Weight Calculations. Animals were weighed daily prior
to treatment. In the IRI + PH group the resected liver mass
was weighed after PH. The initial total liver weight was
calculated as follows:
Resected liver weight
50
∗ 100 (g) . (1)
At time of sacrifice the animals, and in the IRI + PH
group also their regenerated liver mass, were weighed. The
percentage of reconstitution of the liver was calculated by
Regenerated liver weight
Initial total liver weight
∗ 100 (%) . (2)
The liver to body weight ratio was calculated by
Regenerated liver weight
Body weight at time of harvest
∗ 100 (%) . (3)
2.5. Immunohistochemistry. BrdU staining (5-bromo-2󸀠-
deoxyuridine is incorporated in the DNA of proliferating
cells) was used to investigate the number of proliferating
hepatocytes. One hour prior to sacrifice, animals were
injected intraperitoneally with 50mg/kg BrdU (B5002,
Sigma-Aldrich). Liver tissue was harvested and processed to
4mm thick formalin fixed, paraffin embedded sections.They
were stained for BrdU using the following staining protocol:
antigen retrieval was achieved by boiling the sections in
0.01M sodium citrate, pH 6.0 (microwave 1000 Watt; 1 × 7
and 2 × 3 minutes). Endogenous peroxidase was blocked
by 0.6% H
2
O
2
in PBS for 30 minutes at room temperature,
after which DNA was denatured by incubation for 1 hour
at 37∘C in 0.1M HCl in aqua dest. Aspecific binding was
prevented by 0.5% milk powder supplemented with 0.15%
glycin in PBS (blocking buffer). Sections were incubated
overnight at 4∘C with monoclonal mouse anti-BrdU (Bu20a;
DakoCytomation, Glostrup, Denmark; 1 : 80 in blocking
buffer). The next day sections were incubated for 30 minutes
at room temperature with polyclonal rabbit anti-mouse
IgG/HRP (P0161; DakoCytomation; 1 : 1000 in blocking
buffer). After antibody incubation sections were incubated
with DAB-solution and counterstained with hematoxylin.
Per animal 4 high power fields (HPF; 400x) were analyzed
for BrdU positive hepatocytes. Liver tissue sections were also
stained with hematoxylin and eosin (H&E) using a standard
staining protocol.
2.6. Serum Analysis of Transaminase Levels. Blood samples
were collected at time of sacrifice in heparin coated micro-
tubes. After collection, samples were centrifuged (19minutes,
1800 rpm) to separate the serum, which was then further
analyzed at the clinical chemical core facility ofTheChildren’s
Hospital of Philadelphia to determine alanine aminotrans-
ferase (ALT) and aspartate aminotransferase (AST) levels.
2.7. Real-Time Quantitative RT-PCR. At time of sacrifice,
liver tissue was stored overnight at 4∘C and thereafter at
−80∘C in Allprotect Tissue Reagent (Qiagen, Valencia, CA,
USA) for RNA preservation. Total RNA was extracted using
Trizol (Qiagen) and chloroform after mechanical disruption
of the tissue. RNA was precipitated in 75% ethanol and
dissolved in RNase-free water. RNA quantity and quality
were analyzed using a NanoDrop ND-1000 (Thermo Fisher
Scientific, Wilmington, DE, USA). One microgram of RNA
was reverse-transcribed to cDNA using an iScript cDNA
Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA).
PCR primers (presented in Table 1) were synthesized by
Isogen Life Science (Maarssen, Netherlands) and Biolegio
(Nijmegen, Netherlands). Real-time quantitative RT-PCR
was performed with a SensiMix SYBR & Fluorescein Kit
(Bioline, London, United Kingdom) and MyIQ real-time
PCR detection system (Bio-Rad Laboratories) according to
the manufacturer’s instruction.
2.8. MSC-CM Mass Spectrometry Analysis. Twenty-five-fold
concentrated serum-free MSC-CM (50-kD molecular cut-
off filters; Amicon Ultra) was used for protein analysis to
elucidate effects ofMSC-CMon IRI and hepatic proliferation.
One-dimension SDS-PAGE gel lanes were cut into 2-mm
slices using an automatic gel slicer and subjected to in-gel
reduction with dithiothreitol, alkylation with iodoacetamide,
and digestion with trypsin (sequencing grade; Promega,
Leiden, Netherlands), essentially as described by Wilm et
al. [23]. Nanoflow LC-MS/MS was performed on 1100 series
capillary liquid chromatography system (Agilent Technolo-
gies, Amstelveen, Netherlands) coupled to an LTQ-Orbitrap
mass spectrometer (Thermo Scientific, USA) operating in
positivemode and equippedwith a nanospray source. Peptide
mixtures were trapped on a ReproSil C18 reversed phase col-
umn (column dimensions 1.5 cm × 100 𝜇m, packed in-house;
Dr. Maisch GmbH, Ammerbuch, Entringen, Germany) at a
flow rate of 8 𝜇L/min. Peptide separation was performed on
ReproSil C18 reversed phase column (column dimensions
15 cm × 50 𝜇m, packed in-house; Dr. Maisch GmbH) using
a linear gradient from 0 to 80% B (A = 0.1% formic acid; B =
80% (v/v) acetonitrile, 0.1% formic acid) in 70min and at a
constant flow rate of 200 nL/min using a splitter.
The column eluent was directly sprayed into the elec-
trospray ionization source of the mass spectrometer. Mass
spectra were acquired in continuum mode; fragmentation of
the peptides was performed in data-dependent mode. Peak
lists were automatically created from raw data files using
the Mascot Distiller software (version 2.3; MatrixScience,
London, UK). The Mascot search algorithm (version 2.2;
MatrixScience) was used for searching against a customized
database containing all IPI human protein sequences (release
2010 09). The peptide tolerance was typically set to 10 ppm
and the fragment ion tolerancewas set to 0.8Da. Amaximum
number of 2 missed cleavages by trypsin were allowed
and carbamidomethylated cysteine and oxidized methionine
were set as fixed and variable modifications, respectively.The
Mascot score cut-off value for a positive protein hit was set
to 65. Individual peptide MS/MS spectra with Mascot scores
below 40 were checked manually and either interpreted
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Table 1: RT-PCR primer sequences.
Gene Name Accession number Primer (forward/reverse)
TNFA Tumor necrosis factor alpha NM 013693 CCCTCACACTCAGATCATCTTCTGCTACGACGTGGGCTACAG
IL6 Interleukin 6 NM 031168 TAGTCCTTCCTACCCCAATTTCCTTGGTCCTTAGCCACTCCTTC
IL1RN Interleukin 1 receptor antagonist NM 031167 GCTCATTGCTGGGTACTTACAACCAGACTTGGCACAAGACAGG
IL10 Interleukin 10 NM 010548 GCTCTTACTGACTGGCATGAGCGCAGCTCTAGGAGCATGTG
CCND1 Cyclin D1 NM 007631 GCGTACCCTGACACCAATCTCCTCCTCTTCGCACTTCTGCTC
TGFB Transforming growth factor beta NM 011577 CTCCCGTGGCTTCTAGTGCGCCTTAGTTTGGACAGGATCTG
KDR Vascular endothelial growth factor receptor 2 NM 010612 TTTGGCAAATACAACCCTTCAGAGCAGAAGATACTGTCACCACC
ANGPT1 Angiopoietin 1 NM 009640 CACATAGGGTGCAGCAACCACGTCGTGTTCTGGAAGAATGA
VEGFA Vascular endothelial growth factor A NM 009505 GCACATAGAGAGAATGAGCTTCCCTCCGCTCTGAACAAGGCT
FLT1 Vascular endothelial growth factor receptor 1 NM 010228 TGGCTCTACGACCTTAGACTGCAGGTTTGACTTGTCTGAGGTT
TBP TATA binding protein NM 013684 AGAACAATCCAGACTAGCAGCAGGGAACTTCACATCACAGCTC
as valid identifications or discarded. Functional analyses
of these peptides were performed using Ingenuity Pathway
Analysis (Ingenuity Systems, Redwood City, CA, USA).
2.9. Statistical Analysis. All data are presented as mean ±
SEMand statistical analyses were performed using theMann-
Whitney test withGraphPad Prism software and𝑝 ≤ 0.05was
considered statistically significant.
3. Results
3.1. Body andLiverWeight after IRIwith orwithout PHAreNot
Affected by MSC-CM. In the IRI alone group, no significant
differences in body weight change were observed (data not
shown). In the IRI + PH group, all animals showed a decrease
in body weight on postoperative days 1 and 2, but without
statistically significant differences between theMSC-CM and
UM treated groups (9.2% versus 10.3% decrease of initial
body weight, 𝑝 = 0.96; Figure 1(a)). Liver weight after PH
increased with 29.0% in the MSC-CM treated group (from
50% to 64.5% of the initial liver weight) and with 21.6% in
the UM group (from 50% to 60.8%, 𝑝 = 0.40; Figure 1(b)). A
similar effect was seen with regard to the liver to body weight
ratio at time of sacrifice (3.0% in the MSC-CM group versus
2.9% in the UM group, 𝑝 = 0.31; Figure 1(c)).
3.2. MSC-CM Treatment Provides Cytoprotective Effects. We
investigated hepatic tissue injury 6 and 24 hours after IRI
alone as well as 48 hours after IRI + PH by analyzing
H&E stained liver tissue sections for signs of necrosis
(accompanied by increased neutrophil infiltration). Sections
were classified based on the percentage of necrotic tissue
(no injury, <25%, 25–50%, 50–75%, or >75% of liver tissue
affected).
At 6 hours after IRI, no statistically significant difference
in the percentage of necrotic tissue was found between the
MSC-CM andUM treatment group, though a trend appeared
toward reduced hepatic injury after MSC-CM treatment
(MSC-CM versus UM treatment: no injury 43% versus 38%,
<25% injury 57% versus 25%, and 50–75% injury 0% versus
38%; 𝑝 = 0.18; Figure 2(a)). Similar results were found 24
hours after IRI (MSC-CM versus UM treatment: no injury
63% versus 50%, <25% injury 25% versus 50%, and 25–50%
injury 13% versus 0%; 𝑝 = 1.00; Figure 2(b)). After IRI +
PH, however, MSC-CM treatment significantly decreased the
percentage of necrotic tissue compared to UM treatment,
with 38% versus 10% of animals showing no signs of injury,
63% versus 50% with <25% injury, and 0% versus 40% with
more than 25% injury at 48 hours after surgery (𝑝 = 0.04;
Figure 2(c)).
Additionally, serum transaminase levelswere investigated
as markers for hepatic injury. In the IRI alone group, serum
ALT levels after 6 hours were 5301 ± 1426 IU/L in the MSC-
CM treated group versus 5225±1654 IU/L in the UM treated
group (𝑝 = 1.00; Figure 3(a)). After 24 hours, ALT levels were
reduced to 229 ± 147 IU/L after MSC-CM treatment versus
229 ± 77 IU/L after UM treatment (𝑝 = 0.23; Figure 3(b)).
Similar results were found for AST levels (𝑝 = 1.00 at 6
hours and 𝑝 = 0.33 at 24 hours, resp.; Figures 3(d) and 3(e)).
In contrast, 48 hours after IRI + PH serum ALT and AST
levels were markedly lower in the MSC-CM treated animals
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Figure 1: Effects of MSC-CM on body and liver weight after IRI + PH. (a) Body weight change from surgery to harvest; (b) harvest liver
weight versus initial liver weight; (c) harvest liver weight to body weight ratio.
compared to the UM treated animals, though differences
did not reach statistical significance (MSC-CM versus UM
treatment: ALT 138±35 IU/L versus 764±399 IU/L,𝑝 = 0.18,
and AST 248 ± 41 IU/L versus 1008 ± 484 IU/L, 𝑝 = 0.14;
Figures 3(c) and 3(f)).
3.3. MSC-CM Treatment Stimulates Hepatocyte Proliferation
after IRI + PH. After loss of liver mass, hepatocytes are
triggered to enter the cell cycle and proliferate until tissue
loss is compensated and homeostasis is restored, showing a
proliferation peak in rodents around day 2 after liver tissue
injury. Hepatocyte proliferation in the IRI alone group was
not increased after 6 hours, independent of the treatment
strategy (0.1% versus 0.1%, 𝑝 = 0.85; Figure 4(a)). After
24 hours, MSC-CM treatment appeared to slightly induce
hepatocyte proliferation, though proliferation levels were still
low and showed no significant difference between treatment
groups (0.19% after MSC-CM treatment versus 0.06% after
UM treatment, 𝑝 = 0.22; Figure 4(b)). In contrast, IRI + PH
resulted in a clear increase in hepatocyte proliferation after
48 hours, with an almost 3-fold higher proliferation index in
the MSC-CM treated animals compared to the UM treated
animals (13.5% versus 5.0%, 𝑝 = 0.002; Figure 4(c)).
3.4. Treatment with MSC-CM Does Not Significantly Affect
Intrinsic Gene Expression Levels. Next, we investigated if
6 Journal of Immunology Research
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Figure 2: Effects of MSC-CM on hepatic tissue injury. H&E stained liver tissue sections were classified based on the percentage of damaged
tissue: no injury, 0–25%, 25–50%, 50–75%, or >75% of liver tissue affected. This figure shows the percentage of animals with a certain injury
score (a) 6 hours after IRI, (b) 24 hours after IRI, and (c) 48 hours after IRI + PH with representative pictures showing approximately 25%
necrotic liver tissue in the UM group compared to no clear necrotic tissue in the MSC-CM group.
treatment with MSC-derived factors affected hepatic expres-
sion levels of inflammation, proliferation, and angiogenesis
related genes. Tumor necrosis factor alpha (TNF-𝛼) and
interleukin 6 (IL-6) are proinflammatory cytokines and
crucial priming factors for hepatocytes to enter the cell cycle.
Downstream in this process, the G1 to S phase transition
is associated with upregulation of several cyclins including
cyclinD, whereas transforming growth factor beta (TGF-𝛽) is
involved in the negative feedback on hepatocyte proliferation.
Vascular endothelial growth factor A (VEGF-A), vascular
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Figure 3: Effects of MSC-CM on serum injury markers. Serum ALT levels at (a) 6 hours after IRI, (b) 24 hours after IRI, and (c) 48 hours
after IRI + PH. Serum AST levels at (d) 6 hours after IRI, (e) 24 hours after IRI, and (f) 48 hours after IRI + PH.
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Figure 4: Effects of MSC-CM on hepatocyte proliferation. Livers were processed for immunohistochemistry on BrdU to quantify hepatocyte
proliferation.This figure shows the percentage of BrdU positive hepatocytes (a) 6 hours after IRI, (b) 24 hours after IRI, and (c) 48 hours after
IRI + PH; ∗𝑝 ≤ 0.05.
endothelial growth factor receptors 1 and 2 (VEGF-R1 and -
R2), and angiopoietin 1 (Ang-1) are relevant factors for the
regeneration of damaged or lost vasculature. Furthermore,
MSCs are described to have anti-inflammatory capacities
with an important role for interleukin 10 (IL-10) and inter-
leukin 1 receptor antagonist (IL-1Ra) [24, 25].
At 6 hours after IRI, MSC-CM treatment downregulated
expression levels of the inflammatory genes TNFA and IL1RN
compared to expression levels in the UM treated group
(TNFA 40% reduction, 𝑝 = 0.33; IL1RN 34% reduction,
𝑝 = 0.51; Figure 5(a)), though results were not statistically
significant. Similarly, in the IRI + PHmodel, downregulation
of TNFA (50% reduction, 𝑝 = 0.37) and IL1RN (33%
reduction, 𝑝 = 0.41) gene expression in the MSC-CM group
was not statistically significant (Figure 5(c)). Furthermore, 48
hours after IRI + PH andMSC-CM treatment a trend toward
upregulation of the cell proliferation stimulating geneCCND1
(1.7-fold increase, 𝑝 = 0.36) was seen versus a downward
trend of the cell cycle inhibiting gene TGFB (21% reduction,
𝑝 = 0.10; Figure 5(d)). None of the proangiogenic genes
VEGFA, FLT1, KDR, and ANGPT1 showed clear differences
at any time point.
3.5. MSC-CM Contains Proteins Related to Hepatic Cell
Proliferation. To elucidate the positive effect of MSC-CM
on hepatic cell proliferation, but absence of amelioration
of early IRI, we examined the secretome of the L-MSCs.
In the conditioned medium, 2060 unique proteins were
identified by Mass Spectrometry, of which 861 related to
molecules in functional networks analyzed using Ingenuity
Pathway Analysis.This functional network analysis showed a
distinct pattern of cellular processes sustained by the MSC-
CM: the top 10 processes were related to (induction of) cell
replication and angiogenesis, rather than (attenuation of)
Journal of Immunology Research 9
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Figure 5: Effects of MSC-CM on hepatic gene expression. Hepatic gene expression levels were determined by quantitative RT-PCR and
normalized against TBP. Expression levels of inflammation related genes at (a) 6 hours after IRI, (b) 24 hours after IRI, and (c) 48 hours after
IRI + PH; (d) expression levels of cell cycle related genes at 48 hours after IRI + PH.
inflammatory pathways. Proteins involved in hepatocyte and
stellate cell proliferation, such asMAPK8,MAPK9,MAPK14,
Akt, C3, C5, CAV1, and IL6, were enriched to a 𝑝 value
<3,56E-22 (Figure 6; complete table of components provided
as Supplementary Table S1, in the Supplementary Material
available online at http://dx.doi.org/10.1155/2015/202975).
4. Discussion
Hepatic ischemia and reperfusion (IRI) injury is a pathologic
phenomenon that may occur in the situation of shock, severe
liver trauma, liver resection under vascular occlusion, and
(partial) liver transplantation. Subsequent elevated levels of
reactive oxygen species (ROS) progress into oxidative stress,
resulting in inflammation, damaged cellular components,
and induction of apoptosis and necrosis of liver cells [26–30].
In recent years protective and regenerative effects of MSC
therapy have been investigated in animal models of cerebral
or myocardial infarction as well as after renal IRI [31–34].
Other reports describe the effectiveness ofMSCs against toxic
liver injury and hepatic failure [9–12, 20, 35]. MSCs appear
to stimulate organ repair by affecting inflammation and
inducing anti-apoptotic effects [24, 36–39].They furthermore
exert immunomodulatory effects on the immune response
processes triggered during reperfusion [40].
Our group previously reported that trophic factors
secreted by MSCs increase hepatocyte proliferation and alter
expression levels of regeneration-related genes after partial
hepatectomy, thereby stimulating liver regeneration [18]. The
current study investigatesMSC-secreted factors in a clinically
relevant small-for-size ischemic liver model. Corresponding
effects on hepatocyte proliferation were foundwith an almost
3-fold increase in BrdU positive cells, despite combined
injury induced by 60 minutes of warm IRI and 50% hepatec-
tomy. Recently, Du et al. described the use of bone marrow-
(BM-) MSC-secreted factors for the first time in a 50% rat
liver transplantationmodel [41]. In this elegant combined IRI
and partial liver resectionmodel, the cold andwarm ischemic
10 Journal of Immunology Research
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Figure 6: Functional analysis of cellular processes altered by L-MSC-conditioned medium. Proteins present in serum-free MSC-CM were
analyzed using Mass Spectrometry. Out of 2060 proteins identified, 861 related to functional networks in Ingenuity Pathway Analysis. Top
cellular processes involved proliferation of hepatocytes and nonparenchymal cells.
times were kept to a minimum (approximately 60 and 16
minutes, resp.), limiting the IRI component. Their results
show similar effects with overall promoted liver regeneration.
Moreover, our findings are in line with studies on injected
MSCs in reduced size ischemic liver models, suggesting
that proliferation stimulating effects are largely caused by
paracrine interference of MSCs [42, 43].
Furthermore, a significant reduction in postischemic
tissue injury after MSC-CM treatment was found in our
combined injury model. This improvement in liver histology
is also described in other small-for-size ischemic models
using either injected MSCs or their secreted factors [41, 42,
44, 45]. Our histologic findings are supported by a clear
decrease in serum transaminase levels in this group. MSCs
thus seem to produce factors that help prevent oxidative stress
to progress into cellular damage and necrosis.
Interesting however are the effects ofMSC-CM early after
IRI alone. Our results show no effects on serum transaminase
levels and only a trend toward reduced tissue injury at 6 hours
after reperfusion. In contrast, studies using bone marrow,
adipose tissue, or umbilical cord derived MSCs in a liver
IRI model have shown that treatment with these cells and/or
their secreted factors significantly decreases serum ALT and
AST levels [46–49]. An explanation for these different results
could be the duration of ischemic injury, which was induced
for 90 minutes in our model, whereas the models described
in literature used 30 to max 60 minutes of ischemia. The
oxidative damage induced by 90 minutes could be too severe
to detect differences at early time points, that is, 6 and 24
hours after reperfusion. Another explanation may be found
in the compounds present in the conditioned medium of
L-MSCs. The identified proteins seem to fit into networks
stimulating hepatocyte and stellate cell proliferation more
prominent than attenuating inflammation or ischemic injury.
Though a trend was seen toward decreased TNF-𝛼 and
IL-1Ra gene expression as well as increased cyclin D1 gene
expression, the beneficial effects ofMSC-CM treatment could
not sufficiently be explained by changes in inflammation
or proliferation related gene expression levels. This is in
contrast with our previous findings on MSC-CM treatment
in a clean partial hepatectomy model and might therefore
be caused by interfering IRI-induced cascades. However,
several other research groups using small-for-size ischemic
liver models reported significant up- or downregulation of
these inflammatory and/or proproliferative genes as early as
6 hours up to 72 hours after reperfusion [41, 45, 50]. In the
current model we chose to investigate changes after 48 hours,
according to the time point at which we found the most
significant induction of proliferation in our previous study.
Probably, changes in cytokine or chemokine gene expression
preceded this peak in proliferation, which could explain the
lack of significant gene expression changes at 48 hours.
Such could also explain the absence of significant gene
expression changes of proangiogenic factors. A little light on
this may further be shed by the recent publication of Hu et
al., showing downregulation of angiopoietin 2 (Ang-2) in the
early phase of liver regeneration (days 0–3) with recovery
of Ang-2 levels during the later phase of liver regeneration
(days 4–8) [51]. Complementary in vitro studies showed that
the hepatoproliferative effect of Ang-2 is regulated through
the decreased expression of TGF-𝛽1. A different mechanism
accounted for the stimulatory effects of Ang-2 on the later
angiogenic phase of liver regeneration whereby Ang-2 upreg-
ulates VEGFR-2 through autocrine stimulation of the Ang-2
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receptor, Tie2. As we determined Ang-1, we may have missed
the effect through TFG-𝛽 during the early phase, whereas the
indirect effect by induced proliferation of nonparenchymal
cells through VEGF-R signaling probably takes 4-5 days to
become evident. Another possible explanation could be that
the substantial presence of angiogenesis related factors in
MSC-CM largely meets the need for proangiogenic factors
after injury and thereby inhibits upregulation of proangio-
genic genes in the recipient. The exact mechanism of how
MSC-secreted factors interferewith tissue injury and repair at
a genomic and molecular level therefore needs to be further
explored. Interestingly, the adenosine receptors ADORA2A
and ADORA3, members of the G protein-coupled receptor
(GPCR) family, were found to be present in the MSC-CM.
These receptors are known for the preconditioning effect in
myocardial ischemia and may play a role here as well.
Significant differences in liver weight reconstitution were
not detected in our study. In contrast, Seki and coworkers,
in their model of MSC treatment after combined IRI and
70% hepatectomy, describe an increase in regenerated liver
weight as early as day 2 [50]. However, they induced only 15
minutes of ischemia compared to 60 minutes in our model,
resulting in significantly lower oxidative stress related injury
and thereby preserving more functional hepatocytes that can
contribute to regeneration by proliferation. On the other
hand, our findings are in line with those of Wang et al. and
Kanazawa et al., showing a significant increase in liver weight
not earlier than three or seven days after surgery, respectively
[44, 45].
Kanazawa and coworkers described their experience with
BM-MSCs in a model of 70% hepatectomy after 40 minutes
of warm ischemia [44]. BM-MSCs were infused in the portal
vein directly after liver resection, resulting in a decrease in
liver tissue injury, including vacuolar changes and necrosis,
and accelerated regeneration. However, as the authors dis-
cuss, the optimal route and dosage of MSC administration
remain unclear. Systemically transplanted MSCs are mostly
trapped in the microvasculature of the lung after intravenous
infusion, because of their size and adhesion potential [52].
Direct injection into the portal vein, on the other hand, seems
effective but might be unsafe. The number of MSCs needed
for therapeutic effects is not known and ranges from 2 to
10 million MSCs per kilogram in small animal experiments,
whereas fatal embolism has been described for injections
exceeding 10 million cells overall [53]. Furthermore, concern
has been raised on the possibility of malignant transforma-
tion of transplanted MSCs [54, 55]. The use of MSC-derived
factors may therefore have important advantages over the use
of MSCs. Potential other advantages are the elimination of
the risk of rejection by the recipient’s immune system, as well
as the feasibility to produce the factors ready-to-use in large
clinical grade quantities. Recent reports also suggest a similar
beneficial effect of treatment with MSC-CM compared to
treatment with MSCs [56, 57].
On the other hand, MSCs may be able to adjust to chang-
ing needs of the recipient, andmuch is still unclear about how
different culture conditions affect the many factors present
in MSC-CM. So far there is no consensus on a standardized
method of production or on the optimal administration route
or dosage of MSC-secreted factors. Furthermore, research on
possible adverse effects is needed, such as overstimulation
of inflammatory responses, hypersensitivity to certain com-
pounds, or interference with metabolic processes. Another
topic for future research should be to determine which (com-
bination of) factors present in MSC-CM are responsible for
the beneficial effects, to further optimize treatment strategies.
The current study was conducted to explore the effects
of MSC-secreted factors on liver regeneration in the setting
of reduced-size ischemic livers and to investigate if any
beneficial effects could be clarified by effects on tissue damage
after ischemia and reperfusion.We found thatMSC-CMdoes
promote liver regeneration, but not through amelioration
of the IRI component. Though the exact mechanisms of
MSC-mediated stimulation of tissue repair are still largely
unclear, our results contribute to the increasing evidence
suggesting an important role of paracrine effects by MSC-
secreted trophic factors.
5. Conclusions
Our study confirms that MSC-secreted factors decrease hep-
atic tissue injury and promote liver regeneration after large
liver resections, even in an ischemia and reperfusion injury
environment. MSC-derived factors represent a promising
strategy for safe and ready-to-use therapeutic intervention
to stimulate organ repair and regeneration in the setting
of small-for-size syndrome and postresectional liver failure.
However, the optimal source of MSCs for this conditioned
medium as well as the dosage still needs to be elucidated.
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